CTOs on the Move


 
Soitec is a world leader in designing and manufacturing high-performance semiconductor materials. The company uses its unique technologies and semiconductor expertise to serve the electronics and energy markets. With 3,600 patents worldwide, Soitec’s strategy is based on disruptive innovation to answer its customers’ needs for high performance, energy efficiency and cost competitiveness. Soitec has manufacturing facilities, R&D centers and offices in Europe, the U.S. and Asia.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.soitec.com
  • 16550 Via Esprillo
    San Diego, CA USA 92127
  • Phone: 858.746.9000

Executives

Name Title Contact Details

Similar Companies

Angelica Brothers Electrical

Angelica Brothers Electrical is a Monson, MA-based company in the Computers and Electronics sector.

JinkoSolar U.S.

JinkoSolar is a leading manufacturer of photovoltaic products with a vertically integrated business model. Their innovative, intelligent manufacturing produces reliable solar panels that deliver savings on electric bills. They are a global industry lea...

XTREME Semiconductor

XTREME Semiconductor is a Marble Falls, TX-based company in the Computers and Electronics sector.

Press Express

Press Express is a Hanover, MD-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.